期刊
INTERNATIONAL IMMUNOPHARMACOLOGY
卷 112, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.intimp.2022.109182
关键词
Acute myelocytic leukemia; All; trans -retinoic acid; Venetoclax; Drug resistance
资金
- Health Commission of Henan Province [SBGJ202003012]
- Henan Provincial Science and Tech- nology Research Project [192102310053, 202102310053]
The combination therapy of all-trans retinoic acid (ATRA) and ABT-199 shows a synergistic antileukemic effect by inducing apoptosis and cell cycle arrest in acute myeloid leukemia (AML) cells. In vivo, this combination therapy prolongs the survival of AML xenograft mice. The study provides a potential treatment strategy and theoretical support for overcoming the clinical ABT-199 resistance problem in AML patients.
Acute myeloid leukemia (AML) is prone to relapse. Targeted therapy with a specific inhibitor of the anti-apoptotic protein Bcl-2 ABT-199 is an effective method for relapsed and refractory patients, but drug resis-tance is likely, which is primarily related to high Mcl-1 and S100A8 expression. All-trans retinoic acid (ATRA) can inhibit Bcl-2 and Mcl-1 expression. The study purpose was to determine whether ATRA can enhance the antileukemia effect of ABT-199 on AML cells. Our data showed that ATRA combined with ABT-199 exerts a synergistic antileukemic effect by inducing apoptosis and cell cycle arrest in AML. In vivo, combination therapy prolonged the survival of AML xenograft mice. The possible mechanism involves promoting apoptosis through downregulation of S100A8 expression by inhibiting the PI3K/AKT signaling pathway. This study provides a potential treatment strategy and theoretical support for overcoming the clinical ABT-199 resistance problem in AML patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据